iTeos Therapeutics (NASDAQ:ITOS) and Calidi Biotherapeutics (NYSE:CLDI) Head-To-Head Review

Calidi Biotherapeutics (NYSE:CLDI) and iTeos Therapeutics (NASDAQ:ITOS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership and analyst recommendations.

Institutional and Insider Ownership

12.5% of Calidi Biotherapeutics shares are owned by institutional investors. Comparatively, 97.2% of iTeos Therapeutics shares are owned by institutional investors. 24.3% of Calidi Biotherapeutics shares are owned by company insiders. Comparatively, 12.5% of iTeos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

Calidi Biotherapeutics has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, iTeos Therapeutics has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Calidi Biotherapeutics and iTeos Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calidi Biotherapeutics	0	0	3	0	3.00
iTeos Therapeutics	0	0	4	0	3.00

Calidi Biotherapeutics currently has a consensus target price of $16.67, suggesting a potential upside of 1,349.28%. iTeos Therapeutics has a consensus target price of $22.25, suggesting a potential upside of 189.71%. Given Calidi Biotherapeutics’ higher probable upside, equities research analysts plainly believe Calidi Biotherapeutics is more favorable than iTeos Therapeutics.

Valuation & Earnings

This table compares Calidi Biotherapeutics and iTeos Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calidi Biotherapeutics	$50,000.00	300.79	-$29.22 million	N/A	N/A
iTeos Therapeutics	$35.00 million	8.02	-$112.64 million	($3.15)	-2.44

Calidi Biotherapeutics has higher earnings, but lower revenue than iTeos Therapeutics.

Profitability

This table compares Calidi Biotherapeutics and iTeos Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Calidi Biotherapeutics	N/A	N/A	-344.45%
iTeos Therapeutics	N/A	-20.11%	-17.50%

About Calidi Biotherapeutics

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.

About iTeos Therapeutics

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.